Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer-Reference-Cited by-同舟云学术

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer

Published:2019-06-13 Issue:1 Volume:19 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Schwartzberg Lee^ORCID,McIntyre Kristi,Wilks Sharon,Puhalla Shannon,O’Shaughnessy Joyce,Berrak Erhan,He Yaohua,Vahdat Linda

Funder

Eisai Inc.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-019-5674-5.pdf

Reference33 articles.

1. Irvin W Jr, Muss HB, Mayer DK. Symptom management in metastatic breast cancer. Oncologist. 2011;16:1203–14.

2. Twelves C, Gradishar WJ, O’Shaughnessy JA, Bramsen B, Lurie RH. Clinical roundtable monograph: effective management of quality of life in metastatic breast cancer. Clin Adv Hematol Oncol. 2014;12(2 suppl 4):1–14.

3. Grabsch B, Clarke DM, Love A, McKenzie DP, Snyder RD, Bloch S, et al. Psychological morbidity and quality of life in women with advanced breast cancer: a cross-sectional survey. Palliat Support Care. 2006;4:47–56.

4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines)®: breast Cancer version 3.2014. Fort Washington: National Comprehensive Cancer Network; 2014.

5. Eisai Inc. Halaven® (eribulin mesylate) injection [prescribing information]. Woodcliff Lake: Eisai Inc; 2014.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab;PharmacoEconomics - Open;2024-03-15

2. Depressive Symptoms and Quality of Life Associated With the Use of Monoclonal Antibodies in Breast Cancer Treatment;Oncology Nursing Forum;2021-09-01

3. Cognitive Functions under Anti-HER2 Targeted Therapy in Cancer Patients: A Scoping Review;Endocrine, Metabolic & Immune Disorders - Drug Targets;2021-08-26

4. Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2021-07

5. A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer;Breast Cancer Research and Treatment;2020-10-06